HC Wainwright Lowers Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price dropped by analysts at HC Wainwright from $27.00 to $18.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 195.08% from the company’s current price. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ FY2029 earnings at ($6.62) EPS.

Several other research firms also recently commented on ENTA. Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $6.10 on Tuesday. The stock has a market capitalization of $129.28 million, a price-to-earnings ratio of -1.11 and a beta of 0.49. Enanta Pharmaceuticals has a 52 week low of $5.70 and a 52 week high of $17.80. The stock’s 50 day moving average price is $9.52 and its two-hundred day moving average price is $11.61.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.33) earnings per share. On average, equities research analysts forecast that Enanta Pharmaceuticals will post -4.73 EPS for the current year.

Insider Activity

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.64% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Krensavage Asset Management LLC raised its position in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after buying an additional 246,736 shares in the last quarter. Geode Capital Management LLC increased its stake in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares during the period. State Street Corp raised its holdings in Enanta Pharmaceuticals by 6.4% in the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after acquiring an additional 27,147 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $1,243,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth $903,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.